How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance
British Journal of Haematology · 2025-06 · 206 (6) · 1560-1570
DOI: 10.1111/bjh.20101 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Haematology, online erschienen am 24.04.2025. Verfasst von Julia Weisinger und 4 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Référence des Microangiopathies Thrombotiques et Service d'hématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and So…. Hauptthemen laut MEDLINE: Rituximab, Purpura, Thrombotic Thrombocytopenic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Plan for Rare Diseases of the French Ministry of Health, Filière de Santé Maladies Rares Immuno-Hématologiques, French Ministry of Health.
Abstract (Originalsprache)
The use of rituximab, a B‐cell‐depleting agent as a pre‐emptive treatment in immune‐mediated thrombotic thrombocytopenic purpura (iTTP), is the current standard of care. However, for patients refractory to rituximab or for those with contraindications, further treatment guidelines are scarce. Standard immunosuppressive or chemotherapeutic agents were used routinely in the past, but most of the data proving their efficacy are stemming from experience before the routine use of rituximab. Ciclosporin A and azathioprine seem to be effective in the pre‐emptive setting, but their safety profile might limit their use. Extended or intensive rituximab administration may overcome refractoriness in some patients. New therapeutic options, such as new generation anti‐CD20 antibodies like obinutuzumab or the plasma cell‐directed therapy daratumumab, showed important efficacy in iTTP after rituximab failure, with a favourable safety profile. There are no available comparative studies for pre‐emptive treatment options in iTTP; therefore, data from large databases and multicentre studies are essential. In this review, we summarize the possible treatment options in case of rituximab failure in iTTP and try to provide a recommendation based on available literature and our own experience.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Référence des Microangiopathies Thrombotiques et Service d'hématologie, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris and Sorbonne Université, Paris, France.
- Service d'Immunologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
- INSERM Unité Mixte de Recherche (UMRS) 1138, Centre de Recherche des Cordeliers, Paris, France.
- Service d'Hématologie biologique, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris Nord, Université Paris Cité, Paris, France.
ORCID-Profile: Julia Weisinger, Paul Coppo
Förderung
- National Plan for Rare Diseases of the French Ministry of Health
- Filière de Santé Maladies Rares Immuno-Hématologiques
- French Ministry of Health
- European Union MSCA TOLERATE
Zitieren
APA
Weisinger, J., Fadlallah, J., Joly, B., Veyradier, A., & Coppo, P. (2025). How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. British Journal of Haematology, 206(6), 1560-1570. https://doi.org/10.1111/bjh.20101
Vancouver
Weisinger J, Fadlallah J, Joly B, Veyradier A, Coppo P. How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance. British Journal of Haematology. 2025;206(6):1560-1570. doi:10.1111/bjh.20101
BibTeX
@article{Weisinger2025,
author = {Weisinger, Julia and Fadlallah, Jehane and Joly, Bérangère and Veyradier, Agnès and Coppo, Paul},
title = {How we manage immune‐mediated thrombotic thrombocytopenic purpura after rituximab failure or intolerance},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {6},
pages = {1560--1570},
doi = {10.1111/bjh.20101}
}
EUVIMED